

## New CB2 agonists for the Inflammatory Bowel Diseases treatment—Development of an active drug-candidate *per os*



### Keywords

- CB2 agonists
- Inflammatory bowel diseases



### Intellectual Property

- Priority patent application FR 3 022 245 filed on 12.06.2014
- International patent application WO 2015 /189523



### Development Status

- POC on two relevant animal models for IBD and good ADMET, PK/PD results
- Preclinical phase



### Partnership

Licensing

### Technology

CB2 receptor is highly expressed in immune system and intestinal epithelium cells.

This receptor plays an important role in inflammation.

Studies have shown that a particular selective CB2 receptor agonist reduces colon inflammation in models of colitis induced by mustard oil or by dextran sulfate sodium (DSS).

Many pharmaceutical companies consider the CB2 receptor as a therapeutic target of interest for the treatment of chronic inflammatory diseases or neurodegenerative diseases.



### Benefits

- Anti-inflammatory activities
- Enhanced affinity versus competitors compounds
- Better efficiency than the referent molecules
- No cytotoxicity *in vitro*
- Efficiency of *per os* treatment *in vivo*
- Topic treatment (does not pass into the bloodstream)

### Applications

- Inflammatory Bowel Diseases
- Sclerosis,
- Alzheimer's disease,
- Hepatic fibrosis,
- Cancer,
- Osteoporosis,
- Atopic Dermatitis,
- Liver diseases

contact

**Anthony DACCACHE**

Business Developer

+33 6 13 84 39 39

anthony.daccache@sattnord.fr

find other technologies on  
[www.sattnord.fr](http://www.sattnord.fr)



SATT Nord

2 rue du Priez – 59000 LILLE – France  
+33 3 28 36 04 68 – [tech@sattnord.fr](mailto:tech@sattnord.fr)